PURIFYING THERAPEUTIC MONOCLONAL ANTIBODIES

Experiments were perfonned with a prototype membrane having optimal pore size and charge density to determine process conditions that would provide a yield greater than 95% for this step and CHOP levels less than 10 ng of CHOP per mg of mAb in the final bulk. Solution conditions were such that the p...

Full description

Saved in:
Bibliographic Details
Published in:Chemical engineering progress 2008-05, Vol.104 (5), p.S14
Main Authors: Mehta, Amit, Tse, Martha Lovato, Fogle, Jace, Len, Amy, Shrestha, Roshan, Fontes, Nuno, Lebreton, Bénédicte, Wolk, Bradley, van Reis, Robert
Format: Article
Language:English
Subjects:
Cell culture
Chemical engineering
Chromatography
Cost reduction
Costs
Filters
Ligands
Monoclonal antibodies
Optimization
Pore size
Product quality
Proteins
Raw materials
Resins
Viruses
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by
cites
container_end_page
container_issue 5
container_start_page S14
container_title Chemical engineering progress
container_volume 104
creator Mehta, Amit
Tse, Martha Lovato
Fogle, Jace
Len, Amy
Shrestha, Roshan
Fontes, Nuno
Lebreton, Bénédicte
Wolk, Bradley
van Reis, Robert
description Experiments were perfonned with a prototype membrane having optimal pore size and charge density to determine process conditions that would provide a yield greater than 95% for this step and CHOP levels less than 10 ng of CHOP per mg of mAb in the final bulk. Solution conditions were such that the positively charged mAb was retained hy the membrane while neutral or weakly charged CHOP passed through it.
format article
fullrecord <record><control><sourceid>proquest</sourceid><recordid>TN_cdi_proquest_miscellaneous_221581522</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1584903921</sourcerecordid><originalsourceid>FETCH-LOGICAL-p187t-b2230a7cd369db09470a1982bcbaaeaf84d2dd846db478bbbaaefb6d389490d03</originalsourceid><addsrcrecordid>eNotjU9LwzAcQMNQWJ1-h952kMAv_5rkWGu3BWozZnvwNJImhUl102zfX4eeHrzDezOUEc0FBkngBmXACsCSSjFHdym9AxBBlMjQ47bfmdWbadd5t6l35bbuO1PlL7a1VWPbssnLtjNP9tnUr_fodnRTig__XKB-VXfVBjd2baqywSei5Bl7Shk4OQRW6OBBcwmOaEX94J2LblQ80BAUL4LnUnl_taMvAlOaawjAFmj51z19H78uMZ33H4c0xGlyn_F4SXtKiVBE_G5-APq-PSU</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>221581522</pqid></control><display><type>article</type><title>PURIFYING THERAPEUTIC MONOCLONAL ANTIBODIES</title><source>Alma/SFX Local Collection</source><creator>Mehta, Amit ; Tse, Martha Lovato ; Fogle, Jace ; Len, Amy ; Shrestha, Roshan ; Fontes, Nuno ; Lebreton, Bénédicte ; Wolk, Bradley ; van Reis, Robert</creator><creatorcontrib>Mehta, Amit ; Tse, Martha Lovato ; Fogle, Jace ; Len, Amy ; Shrestha, Roshan ; Fontes, Nuno ; Lebreton, Bénédicte ; Wolk, Bradley ; van Reis, Robert</creatorcontrib><description>Experiments were perfonned with a prototype membrane having optimal pore size and charge density to determine process conditions that would provide a yield greater than 95% for this step and CHOP levels less than 10 ng of CHOP per mg of mAb in the final bulk. Solution conditions were such that the positively charged mAb was retained hy the membrane while neutral or weakly charged CHOP passed through it.</description><identifier>ISSN: 0360-7275</identifier><identifier>EISSN: 1945-0710</identifier><language>eng</language><publisher>New York: American Institute of Chemical Engineers</publisher><subject>Cell culture ; Chemical engineering ; Chromatography ; Cost reduction ; Costs ; Filters ; Ligands ; Monoclonal antibodies ; Optimization ; Pore size ; Product quality ; Proteins ; Raw materials ; Resins ; Viruses</subject><ispartof>Chemical engineering progress, 2008-05, Vol.104 (5), p.S14</ispartof><rights>Copyright American Institute of Chemical Engineers May 2008</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>780,784</link.rule.ids></links><search><creatorcontrib>Mehta, Amit</creatorcontrib><creatorcontrib>Tse, Martha Lovato</creatorcontrib><creatorcontrib>Fogle, Jace</creatorcontrib><creatorcontrib>Len, Amy</creatorcontrib><creatorcontrib>Shrestha, Roshan</creatorcontrib><creatorcontrib>Fontes, Nuno</creatorcontrib><creatorcontrib>Lebreton, Bénédicte</creatorcontrib><creatorcontrib>Wolk, Bradley</creatorcontrib><creatorcontrib>van Reis, Robert</creatorcontrib><title>PURIFYING THERAPEUTIC MONOCLONAL ANTIBODIES</title><title>Chemical engineering progress</title><description>Experiments were perfonned with a prototype membrane having optimal pore size and charge density to determine process conditions that would provide a yield greater than 95% for this step and CHOP levels less than 10 ng of CHOP per mg of mAb in the final bulk. Solution conditions were such that the positively charged mAb was retained hy the membrane while neutral or weakly charged CHOP passed through it.</description><subject>Cell culture</subject><subject>Chemical engineering</subject><subject>Chromatography</subject><subject>Cost reduction</subject><subject>Costs</subject><subject>Filters</subject><subject>Ligands</subject><subject>Monoclonal antibodies</subject><subject>Optimization</subject><subject>Pore size</subject><subject>Product quality</subject><subject>Proteins</subject><subject>Raw materials</subject><subject>Resins</subject><subject>Viruses</subject><issn>0360-7275</issn><issn>1945-0710</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2008</creationdate><recordtype>article</recordtype><recordid>eNotjU9LwzAcQMNQWJ1-h952kMAv_5rkWGu3BWozZnvwNJImhUl102zfX4eeHrzDezOUEc0FBkngBmXACsCSSjFHdym9AxBBlMjQ47bfmdWbadd5t6l35bbuO1PlL7a1VWPbssnLtjNP9tnUr_fodnRTig__XKB-VXfVBjd2baqywSei5Bl7Shk4OQRW6OBBcwmOaEX94J2LblQ80BAUL4LnUnl_taMvAlOaawjAFmj51z19H78uMZ33H4c0xGlyn_F4SXtKiVBE_G5-APq-PSU</recordid><startdate>20080501</startdate><enddate>20080501</enddate><creator>Mehta, Amit</creator><creator>Tse, Martha Lovato</creator><creator>Fogle, Jace</creator><creator>Len, Amy</creator><creator>Shrestha, Roshan</creator><creator>Fontes, Nuno</creator><creator>Lebreton, Bénédicte</creator><creator>Wolk, Bradley</creator><creator>van Reis, Robert</creator><general>American Institute of Chemical Engineers</general><scope>3V.</scope><scope>4S-</scope><scope>4T-</scope><scope>7TA</scope><scope>7U5</scope><scope>7WY</scope><scope>7XB</scope><scope>883</scope><scope>88I</scope><scope>8AF</scope><scope>8AO</scope><scope>8FD</scope><scope>8FE</scope><scope>8FG</scope><scope>8FK</scope><scope>8FL</scope><scope>ABJCF</scope><scope>ABUWG</scope><scope>AEUYN</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>BEZIV</scope><scope>BGLVJ</scope><scope>CCPQU</scope><scope>D1I</scope><scope>DWQXO</scope><scope>F28</scope><scope>FR3</scope><scope>FRNLG</scope><scope>GNUQQ</scope><scope>HCIFZ</scope><scope>JG9</scope><scope>K60</scope><scope>K6~</scope><scope>KB.</scope><scope>L.-</scope><scope>L6V</scope><scope>L7M</scope><scope>M0F</scope><scope>M2P</scope><scope>M7S</scope><scope>PDBOC</scope><scope>PQBIZ</scope><scope>PQBZA</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PTHSS</scope><scope>Q9U</scope><scope>S0X</scope></search><sort><creationdate>20080501</creationdate><title>PURIFYING THERAPEUTIC MONOCLONAL ANTIBODIES</title><author>Mehta, Amit ; Tse, Martha Lovato ; Fogle, Jace ; Len, Amy ; Shrestha, Roshan ; Fontes, Nuno ; Lebreton, Bénédicte ; Wolk, Bradley ; van Reis, Robert</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-p187t-b2230a7cd369db09470a1982bcbaaeaf84d2dd846db478bbbaaefb6d389490d03</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2008</creationdate><topic>Cell culture</topic><topic>Chemical engineering</topic><topic>Chromatography</topic><topic>Cost reduction</topic><topic>Costs</topic><topic>Filters</topic><topic>Ligands</topic><topic>Monoclonal antibodies</topic><topic>Optimization</topic><topic>Pore size</topic><topic>Product quality</topic><topic>Proteins</topic><topic>Raw materials</topic><topic>Resins</topic><topic>Viruses</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Mehta, Amit</creatorcontrib><creatorcontrib>Tse, Martha Lovato</creatorcontrib><creatorcontrib>Fogle, Jace</creatorcontrib><creatorcontrib>Len, Amy</creatorcontrib><creatorcontrib>Shrestha, Roshan</creatorcontrib><creatorcontrib>Fontes, Nuno</creatorcontrib><creatorcontrib>Lebreton, Bénédicte</creatorcontrib><creatorcontrib>Wolk, Bradley</creatorcontrib><creatorcontrib>van Reis, Robert</creatorcontrib><collection>ProQuest Central (Corporate)</collection><collection>BPIR.com Limited</collection><collection>Docstoc</collection><collection>Materials Business File</collection><collection>Solid State and Superconductivity Abstracts</collection><collection>ABI/INFORM Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>ABI/INFORM Collection</collection><collection>Science Database (Alumni Edition)</collection><collection>STEM Database</collection><collection>ProQuest Pharma Collection</collection><collection>Technology Research Database</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Technology Collection</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ABI/INFORM Collection (Alumni Edition)</collection><collection>Materials Science &amp; Engineering Collection</collection><collection>ProQuest Central (Alumni)</collection><collection>ProQuest One Sustainability</collection><collection>ProQuest Central</collection><collection>ProQuest Central Essentials</collection><collection>ProQuest Central</collection><collection>Business Premium Collection</collection><collection>Technology Collection</collection><collection>ProQuest One Community College</collection><collection>ProQuest Materials Science Collection</collection><collection>ProQuest Central</collection><collection>ANTE: Abstracts in New Technology &amp; Engineering</collection><collection>Engineering Research Database</collection><collection>Business Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>SciTech Premium Collection</collection><collection>Materials Research Database</collection><collection>ProQuest Business Collection (Alumni Edition)</collection><collection>ProQuest Business Collection</collection><collection>Materials Science Database</collection><collection>ABI/INFORM Professional Advanced</collection><collection>ProQuest Engineering Collection</collection><collection>Advanced Technologies Database with Aerospace</collection><collection>ABI/INFORM Trade &amp; Industry</collection><collection>ProQuest Science Journals</collection><collection>Engineering Database</collection><collection>Materials Science Collection</collection><collection>One Business (ProQuest)</collection><collection>ProQuest One Business (Alumni)</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>Engineering Collection</collection><collection>ProQuest Central Basic</collection><collection>SIRS Editorial</collection><jtitle>Chemical engineering progress</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Mehta, Amit</au><au>Tse, Martha Lovato</au><au>Fogle, Jace</au><au>Len, Amy</au><au>Shrestha, Roshan</au><au>Fontes, Nuno</au><au>Lebreton, Bénédicte</au><au>Wolk, Bradley</au><au>van Reis, Robert</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>PURIFYING THERAPEUTIC MONOCLONAL ANTIBODIES</atitle><jtitle>Chemical engineering progress</jtitle><date>2008-05-01</date><risdate>2008</risdate><volume>104</volume><issue>5</issue><spage>S14</spage><pages>S14-</pages><issn>0360-7275</issn><eissn>1945-0710</eissn><abstract>Experiments were perfonned with a prototype membrane having optimal pore size and charge density to determine process conditions that would provide a yield greater than 95% for this step and CHOP levels less than 10 ng of CHOP per mg of mAb in the final bulk. Solution conditions were such that the positively charged mAb was retained hy the membrane while neutral or weakly charged CHOP passed through it.</abstract><cop>New York</cop><pub>American Institute of Chemical Engineers</pub></addata></record>
fulltext fulltext
identifier ISSN: 0360-7275
ispartof Chemical engineering progress, 2008-05, Vol.104 (5), p.S14
issn 0360-7275
1945-0710
language eng
recordid cdi_proquest_miscellaneous_221581522
source Alma/SFX Local Collection
subjects Cell culture
Chemical engineering
Chromatography
Cost reduction
Costs
Filters
Ligands
Monoclonal antibodies
Optimization
Pore size
Product quality
Proteins
Raw materials
Resins
Viruses
title PURIFYING THERAPEUTIC MONOCLONAL ANTIBODIES
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-10T14%3A45%3A37IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=PURIFYING%20THERAPEUTIC%20MONOCLONAL%20ANTIBODIES&rft.jtitle=Chemical%20engineering%20progress&rft.au=Mehta,%20Amit&rft.date=2008-05-01&rft.volume=104&rft.issue=5&rft.spage=S14&rft.pages=S14-&rft.issn=0360-7275&rft.eissn=1945-0710&rft_id=info:doi/&rft_dat=%3Cproquest%3E1584903921%3C/proquest%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-p187t-b2230a7cd369db09470a1982bcbaaeaf84d2dd846db478bbbaaefb6d389490d03%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=221581522&rft_id=info:pmid/&rfr_iscdi=true